Article

Pathway-based polygenic risk implicates GO: 17144 drug metabolism in recurrent depressive disorder

2017-10-26

Abstract excerpt

The Psychiatric Genomics Consortium (PGC) has made major advances in the molecular etiology of MDD, confirming that MDD is highly polygenic, with any top risk loci conferring a very small proportion of variance in case-control status (1). Pathway enrichment results from PGC meta-analyses can also be used to help inform molecular drug targets. Prior to any knowledge of molecular biomarkers for MDD, drugs targeting...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f39a6e3d-dead-526b-8e0e-452c25a920d4
DOI: 10.1101/209544

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pathway-based polygenic risk implicates GO: 17144 drug metabolism in recurrent depressive disorderDOI 10.1101/209544Read

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment.Semantic proximity Read

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read

Polygenic Risk Score Analysis for Major Depressive Disorder in a Chinese Cohort: Single-Phenotype and Pathway-Based ApproachesSemantic proximity Read

Phenome-wide investigation of bidirectional causal relationships between major depressive disorder and common human diseases.Semantic proximity Read

A Combined Pathway and Regional Heritability Analysis Indicates NETRIN1 Pathway Is Associated With Major Depressive Disorder.Semantic proximity Read

The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes.Semantic proximity Read

From pharmacokinetic genes to polygenic scores and multi-omic integration: advances toward precision psychiatry.Semantic proximity Read

Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response MarkersSemantic proximity Read

Genome-wide pathway analysis in major depressive disorder.Semantic proximity Read

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorderSemantic proximity Read

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorderSemantic proximity Read

Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response.Semantic proximity Read